Missouri Chamber advocates biosimilar legislation and secures unanimous support in the Missouri Senate
The Missouri Senate has given unanimous support to a Missouri Chamber priority, Senate Bill 875. The legislation is intended to modernize Missouri law to allow safe substitutions for biologic medicines.
“We believe a coherent policy outlining the parameters and process for safe substitution of interchangeable biologics for all health care stakeholders – prescribers, pharmacists, payers and manufacturers – will ensure patients have access to high quality, safe and effective medicines,” said Dan Mehan, Missouri Chamber president and CEO. “Missouri has an opportunity to become a respected leader in both the research and manufacture of biologics and biosimilars if our state laws are consistent and aligned with other pro-business states.”
The legislation now heads to the Missouri House for review by committee. A similar bill, House Bill 1366, has been passed by the Missouri House and awaits a hearing by a Senate committee.
For more information on this issue, contact Brad Green, Missouri Chamber director of regulatory affairs, at firstname.lastname@example.org, or by phone at 573-634-3511.